Consequently, while reducing IGF-1 levels may be advantageous in the context of cancer prevention, it could be detrimental by exacerbating muscle wasting (cachexia) in cancer patients or impairing muscle growth in healthy individuals [74]. The gene discussed is IGF1; the disease is cancer.